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Abstract 
Introduction: While the majority of the vascular endothelial growth factor (VEGF) and mammalian target of 
rapamycin (mTOR) inhibitors currently used for the therapy of metastatic renal cell carcinoma (mRCC) are 
small molecule agents inhibiting multiple targets, monoclonal antibodies are inhibitors of specific targets, 
which may decrease off-target effects while preserving on-target activity. A few monoclonal antibodies have 
already been approved for mRCC (bevacizumab, nivolumab), while many others may play an important role 
in the therapeutic scenario of mRCC. 
Areas covered: This review describes emerging monoclonal antibodies for treating RCC. Currently, 
bevacizumab, a VEGF monoclonal antibody, is approved in combination with interferon for the therapy of 
metastatic RCC, while nivolumab, a Programmed Death (PD)-1 inhibitor, is approved following prior VEGF 
inhibitor treatment. Other PD-1 and PD-ligand (L)-1 inhibitors are undergoing clinical development.  
Expert opinion: Combinations of inhibitors of the PD1/PD-L1 axis with VEGF inhibitors or cytotoxic T-
lymphocyte antigen (CTLA)-4 inhibitors have shown promising efficacy in mRCC. The development of 
biomarkers predictive for benefit and rational tolerable combinations are both important pillars of research 
to improve outcomes in RCC. 
1. Introduction 
RCC originates from the renal tubular epithelium and accounts for approximately 85% of kidney cancers and 
for 1.9% of all cancers diagnosed worldwide. Clear cell (cc)-RCC is the most common histologic type. In the 
United States, RCC is the eighth and the sixth most frequent cancer in women and men, respectively, and its 
incidence has been rising by 1.6% a year since the year 2000 [1, 2]. While patients with localized[3] or locally 
advanced[4] kidney cancer have a possibility for cure by undergoing radical surgery, most of the patients 
with metastatic RCC eventually succumb to the disease, with a median overall survival of 18 to 26 months in 
patients treated with first-line anti- VEGF agents[5].  Multiple VEGF and mTOR inhibitors have supplanted 
cytokines as the cornerstone of therapy for cc-RCC. VEGF inhibitors include small molecule VEGF receptor 
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tyrosine kinase inhibitors (TKIs) sunitinib, pazopanib, sorafenib and axitinib, and the monoclonal antibody, 
bevacizumab, while mTOR inhibitors include temsirolimus and everolimus [6-17]. The median progression 
free survival (PFS) with first-line sunitinib, pazopanib or bevacizumab plus interferon is 8 to 11 months, while 
second-line axitinib or everolimus yield a median PFS of 4-5 months. High dose interleukin (IL)-2 remains an 
option in highly selected patients [18].  Additional survival increments have occurred in 2015 in the salvage 
therapy space by the emergence of cabozantinib, a MET, AXL and VEGF receptor targeting TKI, and 
nivolumab, an anti PD-1 targeting monoclonal antibody, for patients with progression following VEGF 
inhibitors [19, 20].  
The importance of monoclonal antibodies for the treatment of solid malignancies has progressively 
increased over the past 20 years[21]. Soluble ligands, such as VEGF, membrane antigens of immune cells, 
such as CD-20 or CTLA4, or surface cancer proteins, such as HER2-neu and EGFR have been successfully 
targeted using monoclonal antibodies approved for clinical use[22-26]. The availability of monoclonal 
antibodies has expanded the possibilities to manufacture therapeutic agents directed against a specific 
molecular target, with a different and often more favorable toxicity profile vs. conventional chemotherapy or 
immunotherapy agents. This review describes emerging monoclonal antibodies for treating RCC. Multiple 
PD-1 and PD-L1 inhibitors are undergoing clinical development, and combinations of inhibitors of the 
PD1/PD-L1 axis with VEGF inhibitors or CTLA-4 inhibitors are being vigorously investigated. The development 
of biomarkers predictive for benefit and rational tolerable combinations are both important pillars of 
research to improve outcomes in RCC. We review available and emerging monoclonal antibodies for the 
therapy of RCC. 
 
2. Search strategy 
A systematic analysis of the literature was conducted on 1st January 2016 by performing a search of Medical 
Subject Heading (MeSH) terms on PubMed using the MESH terms “Antibodies, Monoclonal” and “Kidney 
Neoplasms”. Reviewed articles were written in English and provided clinical data concerning (1) safety and 
(2) efficacy of monoclonal antibodies employed as therapeutic agents against kidney cancer. Clinical data 
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from prospective, interventional phase 1-4 trials as well from both prospective and retrospective 
observational clinical studies were reviewed. A MESH subsequent search was conducted using the MESH 
terms for each of the monoclonal antibody-based therapeutic agent and “Kidney Neoplasms”. Review 
articles and editorials were excluded from the systematic analysis but were also reviewed in order to identify 
additional original articles of interest. Review articles, editorials, commentaries, non-clinical studies and 
clinical studies not focusing on safety/efficacy of monoclonal antibody-based therapeutic agents were cited 
as necessary to support the clinical findings reported. Only original articles published between 1st January 
2006 and 1st January 2016 were considered for inclusion in the systematic review on PUBMED. Abstracts 
published by the American Society of Clinical Oncology and the European Society of Medical Oncology 
between 1st January 2006 and 1st January 2016 were also considered, but full, peer-reviewed papers were 
given priority for inclusion in this review article. The number of full articles included and excluded by the 
systematic searches conducted using MESH terms on PUBMED is shown in figure 1. A few abstracts (< 10) 
have also been reviewed.  
 
 
 
3. Clinical evidence supporting molecular targets for which approved monoclonal antibodies 
are available 
3.1 VEGF  
Bevacizumab is a monoclonal antibody that inhibits the VEGF signaling pathway, which plays a crucial role in 
renal cell carcinoma[27]. It is approved for the first-line treatment of mRCC in combination with interferon 
on the grounds of the PFS improvement achieved in two separate, similarly designed phase III trials 
comparing bevacizumab + interferon vs. interferon alone. In the randomized, double-blind AVOREN 
trial[28]  enrolling 649 patients with previously untreated mRCC, interferon  plus bevacizumab was 
associated with longer PFS vs. interferon  plus placebo  [10.2 months vs 5.4 months; HR 0.63, 95% 
confidence interval (CI) 0.52-0.75; p=0.0001], with the most commonly reported grade 3 or worse adverse 
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events including fatigue (40 [12%] patients in the bevacizumab group vs 25 [8%] in the control group) and 
asthenia (34 [10%] vs 20 [7%]). Consistent results were obtained in the phase III CALGB 90206 trial or 
bevacizumab + interferon vs. interferon alone[8]. Mature results from either of these two trials failed to 
show an advantage in overall survival (OS) associated with the use of bevacizumab, which has been primarily 
attributed to the confounding effect of subsequent treatments[26, 29, 30]. Although neither of these two 
trials included patients with brain metastases, bevacizumab + interferon showed activity in a case series of 4 
RCC patients with brain metastases[31].  
On the basis of the efficacy of bevacizumab + interferon, subsequent clinical research has focused on the 
feasibility of (1) using different doses of bevacizumab and interferon, (2) administering bevacizumab as a 
single agent, (3) using bevacizumab + interferon in settings other than the first-line setting and (4) combining 
bevacizumab with alternative targeted, immunotherapy and also chemotherapy agents. The contributing 
role of interferon to the efficacy of interferon + bevacizumab is not clear. Evidence from phase II trials 
support the use of bevacizumab alone[32] [33]. Single agent bevacizumab also showed activity patients 
receiving bevacizumab in the second- or third-line setting[34]. Activity of second line therapy based on 
bevacizumab and interferon  was also reported anecdotally in a patient who had progressive disease after 
sunitinib treatment [35].   
In view of the clinical efficacy of mTOR inhibitors in RCC administered as single agents [12, 16], and their 
different toxicity profile with respect to bevacizumab, multiple clinical trials have explored the combination 
of temsirolimus or everolimus with bevacizumab. In 50 untreated and 30 previously treated RCC patients, 
the combined use of bevacizumab and everolimus was associated with a median PFS of 9.1 and 7.1 months, 
respectively.[36] Conversely, accrual was terminated early in a phase II study enrolling 10 patients receiving 
bevacizumab+everolimus after an anti-VEGF agent because of unacceptable toxicity[37], while the RECORD-
2 study randomizing 365 patients to first-line everolimus + bevacizumab or interferon + bevacizumab did not 
show any differences between the two arms, with similar discontinuation rates and exposure to treatment 
[37, 38]. Disappointing results were also associated with the combination of bevacizumab plus 
temsirolimus[39, 40]. The large phase III INTORACT trial conclusively proved that first-line temsirolimus plus 
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bevacizumab was not superior to bevacizumab + interferon[41], while the 4-arm phase II BEST trial did not 
show any difference between bevacizumab alone, bevacizumab plus temsirolimus, bevacizumab plus 
sorafenib or bevacizumab + interferon [42] 
Bevacizumab has also been tested in combination with sunitinib in two phase I trials for the first line 
treatment.  Both Sunitinib and Bevacizumab target the VEGF pathway and demonstrate activity against 
advanced RCC, but the results of both trials were disappointing due to prohibitive toxicities, in particular 
hypertension and vascular events.[43, 44] Although the combination of sunitinib+bevacizumab was also 
reported in a case series[45] in the second-line setting, its further development is not planned based on the 
toxicity concerns deriving from phase I data. Other trials have evaluated the combination of bevacizumab 
with agents not approved in RCC. A phase I trial[46] evaluated treatment using bortezomib plus bevacizumab 
on the hypothesis that bortezomib, a proteasome inhibitor agent that suppresses HIF-1α transcriptional 
activity, could overcome the HIF-1α resistance pathway. The toxicities were manageable and 5 of 20 
evaluable patients showed SD lasting longer than 6 months, with three patients exhibiting a radiographic PR. 
This combination warrants further experimentation [46]. A few studies have also assessed the feasibility of 
combined anti-EGFR and anti-VEGF treatment, on the basis of the results obtained in preclinical models 
suggesting potential synergism[47].  In a series of 50 patients receiving neoadjuvant bevacizumab, alone or 
in combination with erlotinib, no radiological responses were reported, with 9 patients (20.9%) showing 
delayed wound healing 4 weeks postoperatively[48]. A phase II, randomized, double-blind, placebo-
controlled trial assessed the benefit associated with the combined use of erlotinib plus bevacizumab in 104 
patients receiving first-line treatment of mRCC. The most common grade 3/4 adverse events (> 5% of 
patients) were hypertension, rash, proteinuria, diarrhea, and  hemorrhage, with one treatment-related 
death occurring in the bevacizumab + erlotinib arm [gastrointestinal (GI) perforation]. Although the safety 
profile of the combination treatment was acceptable,  bevacizumab + erlotinib did not seem to provide 
additional clinical benefit compared with bevacizumab alone [49]. Bevacizumab has also been combined 
with chemotherapy agents such as capecitabine and gemcitabine[50, 51]  The combination of gemcitabine, 
capecitabine and bevacizumab was evaluated in a phase 2 trial enrolling 29 patients with mRCC, most of 
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whom had been previously treated with a VEGF-TKI. Seven patients (24%) had a PR (the duration was 6 to 22 
months). Median OS and PFS were 9.8 months (95% CI: 6.2, 14.9) and 5.3 months (95% CI: 3.9, 9.9), 
respectively. The regimen was well tolerated, and anticipated toxicities were reported. This combination  
appeared to have moderate activity, particularly in patients in the poor risk group and those previously 
exposed to TKI [52]. Bevacizumab activity was also assessed in combination with chemotherapy (gemcitabine 
and 5-fluorouracil) and immunotherapy (IL-2 and interferon-alfa-2a) for the treatment of 27 patients with 
mRCC. The highest dose tested was gemcitabine 1000 mg/m2 and 5-fluorouracil 600 mg/m2 with 
bevacizumab 10 mg/kg, IL-2 1 MIU/m2 and  interferon -α-2a 3 MIU. The most common adverse events were 
fever, thrombocytopenia and neutropenia. A 33% response rate, measured according to the RECIST criteria, 
was reported[53], which suggests that such a combination should be further explored. Concomitant 
inhibition of the PDGFR, VEGF and EGFR signaling pathways by the use of imatinib, bevacizumab and 
erlotinib has also been explored in a phase I/II trial with no encouraging data[54] Similarly, bevacizumab in 
combination with high or low doses of IL-2 did not show encouraging activity [55] [56]. Reviewed clinical 
trials on bevacizumab are summarized in table 1. 
3.2.  Programmed Death (PD)-1 / PD-ligand (L)-1 
The PD-1 protein is a member of the CD28 family that is expressed by activated T and B cells and binds to its 
ligands PD-L1 (B7-H1) and PD-L2 (B7-DC) expressed on tumor and stromal cells. The immune-inhibitory 
effect associated with the activation of the PD-1 pathway plays an important role in mediating tumor 
immune escape. The PD-1/PD-L1 interaction inhibits T survival, proliferation, and effector functions such as 
cell killing and cytokine release[57], and it can also mediate resistance of tumor cells to the attack of 
cytotoxic lymphocytes[58]. Conversely, T cell responses against tumor-specific antigens are augmented by 
inhibition of PD-L1 (B7-H1) in in vitro models [59]. PD-L1 expression on cancer cells is common in all patients 
with RCC, particularly in patients with biallelic VHL inactivation and sarcomatoid features [60, 61]. Nivolumab 
(BMS-936568, MDX-1106) is a fully human IgG4 monoclonal antibody directed against PD-1 that showed an 
excellent safety profile in several phase I trials conducted in solid tumors [62] [63].  Of note, nivolumab was 
able to provide prolonged responses lasting > 4 years after treatment suspension[64, 65]. In the CheckMate 
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025 trial[66], 821 cc-RCC patients who had been treated with one or two lines of antiangiogenic VEGF 
targeting therapy were randomized to receive intravenous nivolumab (3 mg/ kg every 2 weeks) or oral 
everolimus  (10-mg daily) . Nivolumab vs. everolimus was able to yield an OS of 25.0 months (95% CI, 21.8 to 
not estimable) vs. 19.6 months (95% CI, 17.6 to 23.1). The hazard ratio for death was 0.73 (98.5% CI, 0.57 to 
0.93; P = 0.002), thus meeting the pre-specified criterion for superiority (P≤0.0148). Similarly to other 
immunotherapy agents such as sipuleucel-T in prostate cancer [67, 68], nivolumab yielded an advantage in 
OS, but it did not yield a statistical advantage in PFS. Although a median PFS of approximately 4.5 months 
was reported both in the nivolumab and everolimus groups, in the sub-group of patients who had not 
progressed at 6 months, the median progression-free survival significantly favored nivolumab (15.6 months 
vs. 11.7). The CheckMate 025 trial also allowed therapy beyond RECIST progression which makes the optimal 
duration of treatment an unanswered question [68]. Differently from sipuleucel-T, nivolumab was associated 
with a better response rate with respect to the comparator arm (nivolumab vs. everolimus, 25% vs. 5%; 
P<0.001). Nivolumab showed an excellent safety profile, with severe fatigue and anemia, the most 
frequently reported serious adverse events associated with the use of nivolumab, being reported only in 2% 
of patients. A greater advantage of nivolumab vs. everolimus was reported in patients at poor vs. 
intermediate-good prognosis, with the HR for death of patients at poor prognosis being 0.47, and the HR for 
death of patients at good and intermediate prognosis being 0.89 and 0.73, respectively.  Such a 
heterogeneity did not prove to be statistically significant, and these differences may simply be due to the 
higher number of events of death in patients at poor prognosis. Unfortunately, nivolumab efficacy was not 
related to PD-1 ligand expression levels in the CheckMate 025 trial, although such an evaluation did not take 
into account the heterogeneous expression of PD-1 ligand in primary vs. secondary lesions[69], so the value 
of PD-1 ligand expression in metastases is unknown. Furthermore, PD-1 ligand expression levels did not 
appear to change before and after treatment in another prospective trial involving 91 mRCC patients 
undergoing re-biopsy after receiving different doses of nivolumab[70]. In this regard, it must be 
noted that  Conversely, early clinical deterioration captured by quality of life assessment at 8 weeks 
may be tightly associated with decreased nivolumab efficacy, with a hazard ratio for survival of 0.99 
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vs. 0.68 and 0.62 of nivolumab vs. everolimus, respectively, in patients with worse vs. stable and 
improved scores on the Functional Assessment of Cancer Therapy–Kidney Symptom Index–Disease 
Related Symptoms (FKSI-DRS) after 8 weeks[71]. In the latter trial[70], the biological activity of 
nivolumab was demonstrated by a median percent change in CD3+, CD4+,CD8+ tumor-associated 
lymphocytes of 69%, 180% , and 117%, respectively. The results of an exploratory analysis of the 
outcomes associated with nivolumab treatment beyond progression have been presented at ASCO 2016. 
With a similar proportion of patients receiving (38%) and not receiving (36%) post-progression nivolumab in 
the nivolumab-treated arm, treatment beyond progression was associated with a median overall survival of 
28.1 months vs 15.0 months (P<0.001). These results appear intringuing, although optimal duration of 
nivolumab therapy requires to be defined in adequately designed randomized-controlled trials[72]. 
Reviewed clinical trials on nivolumab are summarized in table 2. 
Pembrolizumab, another humanized monoclonal antibody that prevents the binding of PD-1 to PD-L1/2, 
showed an encouraging safety and activity profile when administered in combination with anti-VEGF TKI 
axitinib in a phase Ib trial enrolling 11 mRCC patients. Diarrhea, headache, hypothyroidism, arthralgia and 
fatigue were the most common adverse events reported, while partial responses or disease stabilization 
were reported in 10 patients[73]. Axitinib has also been combined with another fully human IgG1 anti-PD-L1 
monoclonal antibody, avelumab[74], and such a combination is being currently tested vs. sunitinib in the 
JAVELIN Renal 101 phase III trial (NCT02684006). Bevacizumab has also proven to be safe when administered 
with anti PD-L1 monoclonal antibody atezolizumab [75],  while combinations of sunitinib or pazopanib, and 
PD-1 inhibitors have displayed increased GI and hepatic toxicities [76]  . Furthermore, combinations of 
nivolumab plus ipilimumab (NCT02231749) and atezolizumab plus bevacizumab (NCT02420821) are being 
compared with sunitinib as first-line therapy in phase III trials. 
 
4.0. Clinical evidence supporting molecular targets for which monoclonal antibodies are 
under development 
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4.1.  VEGF and PlGF  
Aflibercept is a recombinant fusion protein consisting of human VEGF receptor extracellular domains fused 
to the Fc portion of human IgG1 that binds to all isoforms of VEGF as well as placental growth factor (PlGF)..A 
phase II trial evaluated aflibercept for mRCC previously exposed to a VEGF TKI [77]. Of 94 patients enrolled, 
59 and 35 received 4 mg/kg and 1 mg/kg doses respectively. At the 4mg/kg dose, 61% of patients were 
progression free at 8 weeks and was considered to merit further study.  
 
4.2.  VEGF receptor (R)-2 
Ramucirumab is a recombinant IgG1 monoclonal antibody that binds VEGFR-2 and blocks the interaction 
between VEGFR-2 and VEGF, thus inhibiting VEGF-related endothelial proliferation and migration.[78] In a 
phase 2 study, single agent ramucirumab was administered to 39 patients with mRCC after failure of a 
previous VEGF TKI. The objective response rate was 5.1% (95% CI, 0.6%-17.3%). The 12-week disease control 
rate was 64.1% (95% CI, 47.2%-78.8%), while the median PFS was 7.1 months (95% CI, 4.1-9.7 months) and 
the median OS was 24.8 months (95% CI, 18.9-32.6 months). The most frequent drug-related adverse events 
were headache, fatigue, hypertension, epistaxis, acute renal failure, hemoptysis, hypertension, infusion 
reaction and proteinuria. Cerebral ischemia, myocardial infarction, cardiorespiratory arrest, hypertensive 
crisis, proteinuria and hemoptysis were among the most serious adverse events. The encouraging activity of 
ramucirumab must be weighed against its toxicity profile when considering further development to treat 
RCC [79]. 
 
4.3.  Endoglin 
Endoglin is a HIF-1-  induced membrane receptor that is highly expressed on proliferating endothelial cells 
and mediates resistance to VEGF pathway inhibitors[80].  TRC105 is an anti-endoglin IgG1 monoclonal 
antibody that enhances the activity of VEGF inhibitors in preclinical models[81]. A phase 1b dose escalation 
study assessed safety, pharmacokinetics, and anti-tumor activity of TRC105 in combination with 
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bevacizumab. Thirty-eight patients with solid tumors were enrolled in this trial. TRC105 and bevacizumab 
were well tolerated at their recommended single agent doses (10 mg/kg). Grade 3 suspected adverse 
reactions included anemia (the dose limiting toxicity of TRC105 established as a single agent), headache (the 
most common adverse event), and fatigue. Fifteen patients who had previously progressed on bevacizumab 
or VEGF receptor tyrosine kinase inhibitor (VEGFR TKI) treatment experienced reductions in tumor volume, 
including two PRs by RECIST, and six remained without progression for longer periods than during their prior 
VEGF inhibitor therapy.TRC105 was well tolerated with bevacizumab and clinical activity was observed in a 
VEGF inhibitor refractory population. [81] An ongoing randomized phase II trial is evaluating the addition of 
TRC105 to second or third line axitinib following previous VEGF TKIs, based on feasibility and preliminary 
evidence of activity of this combination[82].  
4.4.  Carbonic Anhydrase IX 
The carbonic anhydrase IX (CAIX, G250) is a heat-sensitive transmembrane cell-surface antigen expressed on 
more than 85% of RCCs, whose expression is related to overexpression of hypoxia-related molecules, such as 
HIF-1α, and correlates with responsiveness to IL-2 therapy. The role of the RCC immunotherapy base on the 
use of anti-CAIX monoclonal antibody (cG250 or girentuximab) was studied also in addition to other 
established therapy for kidney cancer. A phase I clinical trial was conducted to evaluate safety, 
pharmacokinetic, biodistribution, tumor response rates of cG250 monoclonal antibody in monotherapy. 
Repeated intravenous doses of up to 50 mg/m2 of cG250 were safe. No grade 3 or 4 toxicities and no dose 
limiting toxicities (DLT) occurred. cG250 has a long half-life and targets cc-RCC effectively (cG250 tumour 
localization was evaluated by gamma camera imaging). One patient showed a CR, 9 patients had SD, and 3 
had PD[83].  Unfortunately, an international multicenter phase III trial (ARISER) of 864 patients could not 
demonstrate an improvement in outcomes using adjuvant girentuximab following surgery for localized high 
risk disease[84]. However, in a hypothesis-generating analysis, patients with a high tumor CAIX score 
appeared to derive a benefit with improved disease-free survival. Two clinical trials evaluated the treatment 
based on the monoclonal antibody plus IL-2. Because the suggested working mechanism of anti-G250 
antibody is by antibody dependent cell-mediated cytotoxicity (ADCC) and the number of ADCC effector cells 
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can be increased by a low dose IL-2 pulsing schedule, a multicenter study investigate whether the 
association of these two molecules could improve RCC patients clinical outcomes. Thirty-five patients with 
cc-RCC were enrolled, clinical benefits were achieved in 8 of 35 patients (23%), 3 PR and 5 SD. Mean survival 
was 22 months. In general treatment was well tolerated with little toxicity[85]. The second study evaluated 
monoclonal antibody cG250 (which recognizes the CAIX antigen and induces ADCC) with low dose 
subcutaneous IL-2 in patients with advanced RCC. The primary endpoints of the trial were immunological 
effects and toxicity: an increased percentage of circulating CD3-/CD16+CD56+ NK cells was observed, some 
patients showed enhanced ADCC or lymphokine-activated killer cell activity; weekly cG250 with daily low-
dose subcutaneous IL-2 is well tolerated with no adverse events attributable to cG250. No antitumor 
responses were observed in this trial [86]. However, a phase I/II trial combined the monoclonal antibody 
cG250 and interferon--2a to treat 31 patients with clear cell progressive mRCC. Two patients showed PR 
and 14 patients SD, 1 patient had complete remission lasting at least 17 months, 9 patients had SD of 24 
weeks or longer. The median OS observed was 30 months and the 2-year survival was 
57%. Patients receiving extended treatment showed a significantly longer 2-year survival rate than 
discontinued patients (79 vs. 30%; P=0.0083). In general, treatment was well tolerated with little toxicity[87]. 
 
Two separate studies were conducted to evaluate toxicity and efficacy of the radioimmunotherapy (RIT) 
based on the infusions of lutetium 177-girentuximab, an anti-CAIX monoclonal antibody, in patients with 
mRCC. In the phase 1 trial the maximum tolerated dose (MTD) was determined to be 2405 MBq/m2 (higher 
doses were associated with dose-limiting myelotoxicity). Seventeen of 23 [74%] patients demonstrated SD 3 
months after the treatment, and one patient showed a PR that lasted 9 months. Mean growth of target 
tumor lesions was reduced from 40.4% (95% CI, ± 17.0) to 5.5% (95% CI, ± 5.3; p<0.001) at 3 months after 
the treatment. The phase 2 radioimmunotherapy trial included 14 patients with progressive cc-mRCC, who 
received 177Lu-girentuximab intravenously. The treatment was generally well tolerated but resulted in grade 
3-4 myelotoxicity in most patients. The therapy resulted in disease stabilization in 9 of 14 patients, but 
myelotoxicity (prolonged thrombocytopenia in particular) prevented retreatment in some patients. [88, 89]. 
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In conclusion, RIT with 177Lu-gentuximab may stabilize previously progressive cc-mRCC. Furthermore with the 
111In-gentuximab imaging the radiation absorbed doses to normal tissues and tumor lesions during RIT with 
177Lu-gentuximab can be estimated in order to predict hematologic toxicity after treatment with 177Lu-
gentuximab [90].  
 
 
4.5.  Hepatocyte Growth Factor – MET axis  
Accumulating evidence suggests that the Hepatocyte Growth Factor (HGF)- c-Met pathway is implicated in 
proliferation of RCC tumor cells. In fact, c-Met is frequently expressed and constitutively phosphorylated 
in RCC, and patients with high serum levels of HGF/SF have a poor prognosis[91].[92, 93] AMG 102 is a 
fully human monoclonal antibody that targets HGF/scatter factor (SF), thus preventing its binding to c-
Met. In a phase 2 study by Schoffski et al, 61 patients with mRCC were administered AMG-102 (40 at 
10 mg/kg; 21 at 20 mg/kg), with 92% of them having received previous anti-VEGF therapy. The median PFS 
was 3.7 (1.8-7.6) months at 10 mg/kg and 2.0 (1.8-3.7) months at 20 mg/kg, while the median OS (95% CI) 
was 14.9 (9.4 to not evaluable) months at 10 mg/kg and 17.6 (7.1 to not evaluable) months at 20 mg/kg. 
The most common adverse events, reported in ≥10% of patients, were oedema (45.9%), fatigue (37.7%) 
and nausea (27.9%). Grade 3-4 oedema was the most common grade 3-4 event, occurring in 9.8% of 
patients [94].  Since only one patient had a confirmed PR, the potential usefulness of AMG-102 is unclear, 
and further studies are warranted. 
 
4.6.  5T4 
The oncofoetal trophoblast antigen 5T4 is a transmembrane glycoprotein expressed on a variety of solid 
cancers, such as ovarian, gastric, non-small cell lung, colorectal and RCC, while 5T4 is poorly expressed in 
healthy adult tissues, which makes it an ideal target for antibody-based therapy. Naptumomab estafenatox is 
an immunotoxin consisting of a mutated variant of the superantigen staphylococcal enterotoxin A (SEA/E-
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120), which works as a tumor-targeted superantigen (TTS), linked to a fragment antigen binding (Fab) moiety 
of a monoclonal antibody recognizing the tumor-associated antigen 5T4. Targeting of superantigens towards 
tumors induces a local recruitment of patients’ own cytotoxic T cells, which kill tumor cells directly and 
through accumulation of inflammatory cytokines. The use of Naptumomab estafenatox for RCC appears 
promising because of the high expression of 5T4, with >95% of tumors being positive for this antigen. Thirty-
nine patients were enrolled in the MONO study, a phase I study conducted of naptumomab estafenatox 
(ABR-217620) in monotherapy. Patients with pancreatic cancer, non-small-cell lung cancer and RCC received 
ABR-217620 in escalating doses to determine the MTD, which was 15 μg/kg (RCC). DLTs were fever, 
hypotension, acute liver toxicity, and vascular leak syndrome. Fourteen patients (36%) had SD by RECIST on 
day 56 [95]. In a phase 2/3 trial conducted in UK, RCC patients were randomized to receive naptumomab 
estafenatox (Nap)+interferon (IFN)-α or IFN-α, addition of Nap to IFN-α might prolong OS (HR=0.59, p=0.020) 
and PFS (HR = 0.62, p = 0.016) in a subgroup of patients with low IL-6, a biomarker for immune 
responsiveness, and normal levels of anti-SEA/E-120 antibodies, a biomarker for drug exposure [96]. In 
another phase 2 study, 43 RCC patients were treated with different doses of ABR-214936, a recombinant 
fusion protein of a murine Fab recognising the antigen 5T4 and a modified form of SEA. Treatment was 
associated with well tolerated nausea and moderate fever. Median time to progression (TTP) was 4.0 
months and median survival was 19.7 months, with a 2-year survival of 42% [97].  
4.7.  Cytotoxic T-Lymphocyte Antigen (CTLA)-4 
CTLA4 is a receptor that inhibits the function and proliferation of the T cells. This inhibitory receptor has a 
key role in peripheral tolerance of T cells for both normal and tumor-associated antigens. The potential role 
of antibodies against CTLA4 in patients with mRCC was evaluated in two different trials.  A phase 1 study 
evaluated the combination of sunitinib (50 mg daily for 4 weeks then 2 weeks off or 37.5 mg daily as a 
continuous dose) and tremelimumab (an antibody against CTLA4; 6 mg/kg, 10 mg/kg, or 15 mg/kg ). The 
patients enrolled experienced DLT and one of them suffered a sudden death. Overall, rapid-onset renal 
failure was the most common DLT. Nine of 21 patients who were evaluable for response achieved PRs (43%; 
95% CI, 22%-66%). Due to these results further investigations of tremelimumab plus sunitinib is not 
recommended [98].  The second study was a phase II study of ipilimumab conducted in patients with mRCC 
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(previously treated with IL-2 or not). Major adverse events were enteritis and endocrine deficiencies of 
presumed autoimmune origin, 33% of patients experienced a grade 3 or 4 immune-mediated toxicity. One of 
21 patients receiving the lower dose had a PR, 5 of 40 patients at the higher dose had PRs (95% CI for cohort 
response rate 4% to 27%) and responses were seen also in patients who had previously not responded to IL-
2. Of note, a strong association between autoimmune events and tumor regression was reported (response 
rate was 30% with adverse events, 0% without adverse events) [25]. In one phase II trial, generally pre-
treated patients with mRCC were randomized to receive nivolumab 3 mg/kg + ipilimumab 1 mg/kg (N3I1) or 
nivolumab 1 mg/kg + ipilimumab 3 mg/kg (N1I3) IV Q3W for 4 doses then nivolumab 3 mg/kg IV Q2W until 
progression/toxicity[85]. Grade 3–4 related adverse events occurred in 19 patients and objective response 
rate was 29% with N3 + I1 and 39% with N1 + I3. Thus, nivolumab + ipilimumab showed acceptable safety 
and encouraging durable antitumor activity. A phase III trial is comparing first-line sunitinib versus the N3I1 
regimen. 
 
4.8.  TGF-  
Transforming growth factor- (TGFβ) is a pleiotropic cytokine that is involved in the differentiation, motility 
and adhesion of cancerous cells, as well as in angiogenesis and formation of extracellular matrix. 
Furthermore, it suppresses host antitumor immunity. GC1008 (Fresolimumab) is a human anti-TGFβ 
monoclonal antibody that blocks all the three isoforms of this cytokine. In the phase I study conducted by 
Morris et al., the safety and activity of GC1008 was evaluated in patients with previously treated advanced 
malignant melanoma and RCC. No DLT was observed, and the maximum dose, 15 mg/kg, was determined to 
be safe. Acute infusion reaction, neutropenia, thrombocytopenia, fatigue, diarrhea, vomiting and grade 2 
transaminases or bilirubin elevation were observed but skin toxicity (consisting in eruptive 
keratoacanthomas, hyperkeratosis, cutaneous squamous cell carcinoma and basal cell carcinoma) was the 
most common drug-related adverse events. The median PFS for all 29 patients was 11.1 weeks (range, 4.1–
44.4 weeks). The median TTP/PFS for the PR and SD patients was 24 weeks (range, 16.4–44.4 weeks). 
Further studies of single agent and combination treatments are required[99]. 
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 4.9.  Interleukin (IL)-6 
The multifunctional cytokine IL-6 is elevated in numerous infectious, inflammatory, autoimmune diseases, 
and cancer. It induces tumor growth, angiogenesis, invasion and metastasis. High levels of IL-6 correlate with 
metastatic progression, poorer prognosis and response to IL-2 therapy of renal cancer. As a result, IL-6 may 
serve as a potential therapeutic target. Furthermore, C-reactive protein (CRP), whose synthesis is stimulated 
by IL-6, may serve as a pharmacodynamic (PD) marker of IL-6 activity. Siltuximab is a chimeric monoclonal 
antibody that specifically binds IL-6. A phase I/II study was conducted to evaluate the safety, efficacy, 
pharmacokinetics (PK) and PD of Siltuximab in 68 patients with mRCC. Although only one patient showed a 
PR lasting  approximately 8 months,  approximately 50% of patients had SD that was sustained for a 
minimum of 11 weeks. [100] Siltuximab appeared to be safe in a three-part phase I/II study in patients with 
progressive mRCC, with no MTD or immune response observed. The adverse events reported were fatigue, 
chest pain, back pain, dyspnoea, hypertension, transaminases increased, syncope, pain, musculoskeletal 
pain, and hypercalcaemia. In part 2, SD (11weeks) or better was achieved by 11 out of 17 (65%) 
3 mg/kg treated patients (one PR ∼8 months, 10 SD) and 10 out of 20 (50%) 6 mg/kg treated patients (10 SD). 
In part 3 65% of patients achieved SD. On the basis of these results Siltuximab stabilised disease in >50% of 
progressive mRCC patients. Given the favourable safety profile of siltuximab and poor correlation of tumour 
shrinkage with clinical benefit demonstrated for other non-cytotoxic therapies, further evaluation of dose-
escalation strategies and/or combination therapy may be considered for patients with RCC. [101] 
 
4.10.  TNF- 
Tumor necrosis factor  (TNF-) is an inflammatory cytokine with antitumor activity at high dose.  
Nevertheless, it is secreted by many tumor cells, RCC included, having a role in tumor growth (as autocrine 
growth factor) and metastasis at pathologic levels. Indeed TNF- is associated with resistance, poor 
prognosis and cachexia in cancer patients. Infliximab is a chimeric human-murine monoclonal antibody 
antihuman TNF-, it inhibits the bond between TNF- and its receptors and activates complement-
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mediated cell death. In two sequential phase II trials Infliximab was administered at standard and high 
dose in patients with immunotherapy-resistant or refractory RCC. At standard doses ( 5 mg/kg of 
infliximab), 16% of patients showed PR and another 16% of patients achieved SD Median duration of 
response was 7.7 months. At high doses (10 mg/kg of infliximab), 61% of patients obtained SD, with a 
median duration of response of 6.2 months. Higher doses were associated with grade 1-2 toxicities 
including mucositis, headache, myalgia, anemia, flushing, fatigue, peripheral edema and infection. Higher 
baseline serum levels of TNF- were associated with PD and poor prognosis[102] A phase I/II trial was 
conducted administering infliximab in combination with sorafenib in patients with advanced RCC.  Median 
PFS and OS were 6 (95% CI, 4.8-7.2) and 14 months (95% CI, 10-19), respectively. The most common 
toxicities observed were diarrhea, alopecia, lymphopenia, hand-foot syndrome and rash. Grade 3 adverse 
events were rash, fatigue, hand-foot syndrome and infection. Since no evidence of improved efficacy of 
the combination vs. sorafenib alone in RCC was obtained, the further development of the combination of 
infliximab with sorafenib in advanced RCC was not recommended. [103] 
 
4.11.  CD-70 
CD70 is a member of the TNF ligand family that is expressed on activated antigen presenting cells such as B 
lymphocytes and dendritic cells and binds to the CD27 receptor expressed on T lymphocytes. The CD70 - 
CD27 interaction mediates co-stimulation of NK, B, and T cells and induces differentiation of naive CD4 T 
lymphocytes into IFN-γ producing T helper 1 (Th1) cells [104]. The attractiveness of the CD70-CD27 pathway 
for therapeutic purposes in RCC is based on its role in increasing  the regulatory T cell (Treg) / effector T cell 
(Teff)ratio, thus allowing the tumor to escape immune response[105].   The experimental agent SGN-75 is 
constituted by anti-CD70 IgG1 monoclonal antibody SGN-70 that is chemically bound to the cytotoxic 
compound named monomethyl auristatin F. SGN-75 was evaluated in a phase I dose-escalation study in 
patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or mRCC. Fifty-eight patients were 
enrolled (39 RCC, 19 NHL). Administration every 3 weeks was better tolerated than weekly dosing and the 
MTD in RCC patients was 3 mg/kg. The most common adverse events   generally manageable, included 
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corneal epitheliopathy and dry eye (57% of patients), fatigue (40% of patients), nausea (30% of patients) and 
thrombocytopenia (26% of patients). The antitumor activity was encouraging and included 1 complete 
response (CR), 2 PRs, while 20 patients showed SD, warranting further testing of this agent. Proof of the 
biological activity of SGN-75 was obtained by the observation of a substantial depletion of CD70-
positive peripheral blood lymphocytes after SGN-75 treatment [106]. 
 
 
5.0. Conclusions 
Bevacizumab has been the most extensively investigated monoclonal antibody in RCC, although its use 
according to its label indication is far less frequent in kidney cancer with respect to oral TKIs such as 
sunitinib. This may be due, among other reasons, to the intravenous vs. oral route of administration of 
bevacizumab vs. sunitinib and the approved use of bevacizumab in combination with interferon. 
Furthermore, in a meta-analysis of 11 randomized-controlled trials, a longer PFS was associated with 
sunitinib vs. bevacizumab + IFN-α use (HR = 0.79, 95% CrI: 0.64 - 0.96), and temsirolimus + bevacizumab (HR 
= 0.74, 95% CrI: 0.56 - 0.96), while no difference in PFS between sunitinib and either axitinib, pazopanib or 
tivozanib was reported [107]. Although toxicities associated with bevacizumab make it feasible to combine it 
with multiple targeted, immunotherapy and chemotherapy agents, the evidence suggesting some advantage 
of the use of single agent bevacizumab vs. bevacizumab-containing regimens is scarce. In this regard, the 
results obtained in terms of PFS and OS with gemcitabine-capecitabine-bevacizumab in patients with 
sarcomatoid features [50] are promising and are consistent with those obtained in other clinical trials 
evaluating the combined use of chemotherapy + targeted agents in RCC patients with aggressive 
features[108]. While combination of bevacizumab with mTOR inhibitors is not more effective vs. the use of 
bevacizumab alone, combination of bevacizumab plus oral TKIs such as sunitinib is prohibitively toxic. 
Combination of bevacizumab with novel immunotherapy agents, such as nivolumab and other PD-1/PD-L1 
inhibitors, may be feasible on the grounds of different mechanisms of action and non-overlapping toxicity 
profiles, although the advantages of such a combination treatment must be weighed against its increased 
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financial burden. The immunotherapy agents reviewed here target either surface white blood cells 
molecules with inhibitory activity (PD-1, CTLA-4) or cytokines mediating cancer proliferation or exerting 
immunosuppressive activity. Additional trials are required in order to assess the best combination/sequence 
of use of these and other novel emerging monoclonal antibodies directed against key molecular targets 
involved in immune response and cancer growth.  
 
6.0. Expert opinion 
The use of monoclonal antibodies holds great promise for RCC and may be accompanied by excellent 
therapeutic index. The findings obtained with the monoclonal antibody nivolumab in the CheckMate 025 
trial are unprecedented in the treatment scenario of RCC. Unlike everolimus and axitinib, which failed to 
show any advantage in OS after failure of TKI treatment, nivolumab was able to yield a significant survival 
advantage vs. everolimus, with a hazard ratio for death of 0.73 (98.5% CI, 0.57 to 0.93; P = 0.002). The 
results obtained in the CheckMate trial established a paradigm change for two main reasons. First, the 
intrinsic immunogenicity of RCC has been  successfully exploited for therapeutic purposes via the use of 
novel antibody-based immunotherapy agents, so nivolumab paved the way for experimentation and testing 
of the wealth of immunotherapy agents directed against PD-1 and other additional immunological 
targets[109]. Second, unlike targeted agents, whose clinical activity was primarily based on improvements in 
PFS, nivolumab did not yield any advantage  in PFS, although  its use was associated with increased 
radiological responses (25% vs. 5%; P<0.001). The lack of an association between PFS and OS is similar to 
that associated with another immunotherapy agent, that is Sipuleucel-T, in prostate cancer [68] and 
underlines the need for additional surrogate end points, both clinical and biological, other than PFS. In 
contrast, cabozantinib extended PFS and OS following VEGF inhibitors, although the toxicity profile needs to 
be considered when selecting patients for this agent. Although PD-1 and PD-L1 are the most promising 
therapeutic targets for RCC, we have shown that monoclonal antibodies can also target key cytokines (TNF , 
IL-6, endoglins and TGF-) and surface immune molecules (CTLA-4), although the results obtained with such 
agents are still preliminary. 
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The aforementioned data with monoclonal antibodies needs to be viewed in the context of emerging agents 
and combinations belonging to other classes. For example, the combination of lenvatinib plus everolimus 
was associated with a significantly longer median PFS of 12.9 months compared to 5.6 months with 
everolimus in a randomized phase II trial, with [110, 111]. Finally, given the explosion in the number of 
approved agents and combinations being developed, it is imperative to co-develop precision medicine to 
select the right patient for the right drug or combination. Presently, nivolumab is the most extensively 
studied immunotherapy drug in renal cell carcinoma, but patent rights do not prevent other pharmaceutical 
companies from developing drugs against established therapeutic targets such as PD-L1 and PD-1, which has 
led to sharp increase of the number of monoclonal antibody-based immunotherapy drugs being investigated 
in clinical trials. Differently from the multiple bevacizumab-based treatment combinations which we showed 
failed to provide any additional benefit, combined VEGF and PD-1/PD-L1 inhibition may be the key to 
improving mRCC outcomes in the next 5 years, on the basis of the non overlapping side effects and biological 
targets of the therapeutic agents involved. The increasing costs associated with the availability of multiple 
agents may prevent access to novel effective agents to most patients. On the other hand, a virtuous loop 
may be created by the abundance of multiple monoclonal antibodies directed against the same/similar 
targets (e.g. pembrolizumab, nivolumab, atezolizumab, avelimumab are directed against PD-1/ PD-L1), with 
market competition of similarly effective agents possibly leading to decreased therapy costs. 
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Article highlights Box 
• Monoclonal antibodies hold a great potential for the treatment of metastatic renal cell carcinoma, 
with two agents of this pharmacologic class currently approved (anti-VEGF agent bevacizumab and 
anti-PD-1 agent nivolumab) 
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• Bevacizumab has shown to prolong progression-free survival in the first line setting of treatment of 
metastatic renal cell carcinoma, while nivolumab has shown to prolong overall survival in the 
second-line setting after failure of one anti-VEGF treatment. Bevacizumab has been approved in 
combination with interferon, although the contributing role of interferon to the therapeutic activity 
of the combination is uncertain.  
• A number of studies have been conducted to explore the feasibility to combine bevacizumab with 
agents other than interferon, but none of these have shown promising results 
• Although the PD-1 /PD-L1 axis is the most promising target for the development of novel agents, a 
large number of prospective trials are being conducted to explore the use of monoclonal antibodies 
directed against multiple alternative targets, such as MET, endoglin, 5T4, CTLA-4, CD70, and others 
• Promising results may derive from the combined inhibition of the VEGF and PD1/PD-L1 axis in the 
next 5 years, although the advantages of such as combination must be weighed against its increased 
toxicities and financial costs. 
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Table 1. Clinical trials reviewed 
 
 Experimental 
agent and 
mechanism of 
action 
Study 
design 
Experime
ntal 
combinati
on 
PFS OS Grade 3-4 
toxicities 
Escudier 
et al. 
[22, 24] 
Bevacizumab - 
angiogenesis 
inhibitor by 
blocking 
VEGF-A; 
Interferon α - 
plays an 
antiproliferative 
role activating 
MAP kinase 
signaling, 
increasing p53 
activity and 
modulating 
functions of the 
immune 
system 
 
Multicentre, 
randomize
d, double-
blind, 
phase 3 
trial  
Interferon 
α-2a and 
bevacizu
mab 
versus 
interferon 
α-2a and 
placebo 
10.2 mo 
with 
interferon α-
2a and 
bevacizuma
b; 5.4 mo 
with 
interferon α-
2a and 
placebo 
23.3 mo 
with 
bevacizu
mab and 
interferon 
α-2a; 
21.3 mo 
with 
interferon 
α-2a and 
placebo 
Fatigue (12%), 
asthenia (10%), 
proteinuria 
(8%), 
hypertension 
(6%) with 
interferon α-2a 
and 
bevacizumab; 
fatigue (8%), 
asthenia (7%) 
with interferon 
α-2a and 
placebo 
Rini et 
al. [8, 
23] 
Bevacizumab 
(see above); 
Interferon 
α (see above) 
Prospectiv
e, 
randomize
d, 
multicenter 
phase 3 
trial 
Bevacizu
mab plus 
IFN-α 
versus 
IFN-α 
monother
apy 
8.5 mo (7.5-
9.7) with 
bevacizuma
b plus IFN-
α; 5.2 (3.1-
5.6) with 
IFN-α 
18.3 mo 
(16.5 to 
22.5) with 
bevacizu
mab plus 
IFN-α; 
17.4 mo 
(14.4 to 
20.0) with 
IFN-α 
Fatigue (37%), 
anorexia (17%), 
proteinuria 
(15%), 
hypertension 
(11%), 
neutropenia 
(9%), nausea 
(7%), dyspnea 
(6%) with 
bevacizumab 
plus IFN-α; 
fatigue (30%), 
neutropenia 
(9%), anorexia 
(8%), nausea 
(5%) with IFN-α 
Melichar 
et al. 
[27] 
Bevacizumab 
(see above); 
Interferon 
α (see above) 
Prospectiv
e, 
multicentre, 
open-label, 
single-arm, 
multination
al, phase 2 
trial 
Bevacizu
mab with 
low-dose 
IFN 
15.3 mo 
(11.7-18.0) 
30.7 mo 
(25.7-not 
reached) 
Fatigue or 
asthaenia 
(9.6%) 
Hainswo
rth et al. 
[28] 
Bevacizumab 
(see above) 
Phase 2 
trial 
Bevacizu
mab 
7.8 mo in 
previously 
untreated 
patients; 3.7 
 Proteinuria 
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mo in 
patients 
previously 
treated with 
VEGFR-
targeted 
agents 
Turnbull 
et al. 
[29] 
Bevacizumab 
(see above) 
Retrospecti
ve analysis 
Bevacizu
mab 
4.4 mo (2.8-
9.6) 
19.4 mo 
(9.9-not 
reached) 
Fatigue (29%), 
dehydration 
(24%), failure to 
thrive (10%), 
constipation 
(10%), muscle 
weakness 
(10%) 
Jonasch 
et al. 
[43] 
Bevacizumab 
(see above); 
Erlotinib - 
tyrosine kinase 
inhibitor acting 
on EGFR 
Prospectiv
e, single-
arm, phase 
2 trial 
 Bevacizu
mab plus 
erlotinib 
or 
bevacizu
mab 
alone 
11 mo (5.5-
15.6) 
25.4 mo 
(11.4-not 
estimable
) 
Diarrhea (6%) 
with 
bevacizumab 
plus erlotinib; 
hypertension 
(5%), anemia 
(5%) with 
bevacizumab 
only 
Hainswo
rth et al. 
[31] 
Bevacizumab 
(see above); 
Everolimus - 
inhibits 
mTORC1 
protein 
complex, thus 
prevents tumor 
cells growth 
and 
proliferation 
Multicenter, 
community-
based, 
nonrandom
ized, phase 
2 trial 
Bevacizu
mab and 
everolimu
s 
8.1 mo (6.3-
10.8) 
18.5 mo Proteinuria 
(26%), 
mucositis/stoma
titis (15%), 
fatigue (12%), 
diarrhea (9%), 
anemia (5%), 
hyperlipidemia 
(5%), 
constipation 
(5%) 
Harshm
an et al. 
[32] 
Bevacizumab 
(see above); 
Everolimus 
(see above) 
Investigator
-initiated, 
phase 2 
trial 
Bevacizu
mab and 
everolimu
s 
5.1 mo 21 mo  
Ravaud 
et al. 
[33] 
Everolimus 
(see above); 
Bevacizumab 
(see above); 
Interferon 
α (see above) 
Open-label, 
randomize
d,  phase 2 
trial 
Everolimu
s plus 
bevacizu
mab 
(EVE/BE
V) versus 
interferon 
α-2a plus 
bevacizu
mab 
(IFN/BEV)
9.3 mo with 
EVE/BEV; 
10 mo with 
IFN/BEV 
27.1 mo Proteinuria 
(24.4%), 
stomatitis 
(10.6%), anemia 
(10.6%) with 
EVE/BEV; 
fatigue (17.1%), 
asthenia 
(14.4%), 
proteniuria 
(10.5%) with 
IFN/BEV 
Merchan 
et al. 
[34] 
Bevacizumab 
(see above); 
Temsirolimus - 
mTOR 
inhibitor, 
Phase 2 
trial 
Bevacizu
mab and 
temsirolim
us 
5.9 mo (4.0-
7.8) 
20.6 mo 
(11.5-
23.7) 
Hypertriglycerid
emia (14%), oral 
mucositis 
(10%), fatigue 
(10%), anemia 
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induces cell 
cycle arrest in 
th G1 phase, 
blocks tumor 
angiogenesis 
by reducing 
synthesis of 
VEGF, 
interferes with 
growth, 
survival and 
proliferation of 
tumor cells 
(8%), 
proteinuria (8%) 
Negrier t 
al. [35] 
Bevacizumab 
(see above); 
Temsirolimus 
(see above); 
Interferon 
α (see 
above); Sunitini
b – multi-
targeted 
receptor 
tyrosine kinase, 
it binds PDGF-
Rs, VEGF-Rs, 
c-KIT, RET, G-
CSF-R, FLT-3 
Multicentre, 
open-label, 
randomize
d, phase 2 
trial 
Bevacizu
mab and 
temsirolim
us or 
sunitinib 
or 
bevacizu
mab and 
interferon 
α 
8.2 mo (7.0-
9.6) with 
bevacizuma
b and 
temsirolimu
s; 8.2 mo 
(5.5-11.7) 
with 
sunitinib; 
16.8 mo 
(6.0-26.0) 
with 
interferon 
α and 
bevacizuma
b 
  
Rini et 
al. [36] 
Bevacizumab 
(see above); 
Temsirolimus 
(see above); 
Interferon 
α (see above) 
Radomized
, open-
label, 
multicenter, 
phase 3 
trial 
Bevacizu
mab and 
temsirolim
us versus 
bevacizu
mab and 
interferon 
α  
9.1 mo (8.1-
10.2) with 
temsirolimu
s and 
bevacizuma
b;9.3 mo 
(9.0-11.2) 
with 
bevacizuma
b and 
interferon α 
25.8 mo 
(21.1-
30.7) with 
temsiroli
mus and 
bevacizu
mab; 25.5 
mo (22.4-
30.8) with 
bevacizu
mab and 
interferon 
α 
Proteinuria 
(16%), 
hypertension 
(11%), anemia 
(9%), mucosal 
inflammation 
(8%), 
hypertriglyceride
mia (7%), 
stomatitis (7%), 
hypercholesterol
emia (6%), 
asthenia (6%), 
hyperglycemia 
(6%), fatigue 
(5%) with 
temsirolimus 
and 
bevacizumab; 
proteinuria 
(13%), fatigue 
(11%), 
hypertension 
(10%), asthenia 
(10%), anemia 
(8%), 
neutropenia 
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(8%) with 
bevacizumab 
and interferon α 
Flaherty 
et al. 
[37] 
Bevacizumab 
(see above); 
Temsirolimus 
(see above); 
Sorafenib -  
inhibitor of 
tyrosine 
protein 
kinases, such 
as VEGF-R, 
PDGF-R, Raf 
family kinases 
Randomize
d phase 2 
trial 
Bevacizu
mab 
monother
apy or 
bevacizu
mab plus 
temsirolim
us or 
bevacizu
mab plus 
sorafenib 
or 
temsirolim
us plus 
sorafenib 
7.5 mo (5.8-
10.8) with 
bevacizuma
b 
monotherap
y; 7.6 mo 
(6.7-9.2) 
with 
bevacizuma
b plus 
temsirolimu
s; 9.2 mo 
(7.5-11.4) 
with 
bevacizuma
b plus 
sorafenib; 
7.4 mo (5.6-
7.9) with 
temsirolimu
s plus 
sorafenib 
  
Falchoo
k et al. 
[41] 
Bevacizumab 
(see above); 
Bortezomib - 
proteasome 
inhibitor 
Phase 1 
trial 
Bevacizu
mab plus 
bortezomi
b 
  Thrombocytope
nia (12%) 
Bukows
ki et al. 
[44] 
Erlotinib (see 
above); 
Bevacizumab 
(see above) 
Randomize
d, double-
blind, 
placebo-
controlled, 
phase 2 
trial 
Erlotinib 
plus 
bevacizu
mab 
versus 
bevacizu
mab 
alone 
9.9 mo with 
bevacizuma
b plus 
erlotinib; 8.5 
mo with 
bevacizuma
b alone 
 Hypertension 
(31%), rash 
(16%), diarrhea 
(7.8%), 
proteinuria 
(7.8%), 
hemorrhage 
(5.9%) with 
erlotinib plus 
bevacizumab; 
hypertension 
(26%), 
proteinuria 
(5.7%) with 
bevacizumab 
alone 
Gordon 
et al. 
[56] 
Bevacizumab 
(see above); 
TRC105 - 
inhibits 
endoglin, 
which has a 
role in 
angiogenesis 
Open-label, 
multicenter, 
nonrandom
ized, dose-
finding, 
phase 1 
trial 
Bevacizu
mab and 
TRC105 
  Anemia 
(20.8%), 
headache 
(10.4%), fatigue 
(5.2%) 
Dandam
udi et al. 
Bevacizumab 
(see above); 
Phase 2 
trial 
Bevacizu
mab and 
11,2 mo 
(5.7-11.7) 
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[50] IL-2 - has a 
crucial role in 
modulating 
important 
functions of 
immune 
system, such 
as tolerance 
and immunity, 
through its 
effects on T 
cells 
high-dose 
IL-2 
Garcia 
et al. 
[51] 
Bevacizumab 
(see above); 
IL-2 (see 
above) 
Prospectiv
e, phase 2 
trial 
Bevacizu
mab and 
low-dose 
IL-2 
9.6 mo (4.1-
16.9) 
 Fatigue (42%), 
neutropenia 
(12%) 
Feldman 
et al. 
[38] 
Bevacizumab 
(see above); 
Sunitinib (see 
above) 
Single-
center, 
investigator
-initiated, 
phase 1 
trial 
Bevacizu
mab plus 
sunitinib 
11 mo (6.0-
not 
reached) 
 Hypertension 
(60%), 
proteinuria 
(36%), elevated 
lipase (28%), 
thrombocytopen
ia (24%), hand-
foot-skin 
reaction (16%), 
fatigue (12%), 
hyponatremia 
(12%), 
hemorrhage 
(12%), 
reversible 
posterior 
leukoencephalo
pathy (8%), 
elevated 
amylase (8%), 
rash (8%), 
microangiopathi
c hemolytic 
anemia (8%), 
hyperuricemia 
(8%), abdominal 
pain (8%), 
lymphopenia 
(8%) 
Bruce et 
al. [39] 
Bevacizumab 
(see above); 
Sunitinib (see 
above) 
Multicenter, 
investigator
-initiated, 
phase 1 
trial 
Bevacizu
mab and 
sunitinib 
  Hypertension 
(16.7%), 
leukopenia 
(16.7%), 
diarrhea 
(16.7%), anemia 
(16.7%) 
Medioni 
et al. 
[40] 
Bevacizumab 
(see above); 
Sunitinib (see 
above) 
Case 
report 
Bevacizu
mab and 
sunitinib 
8.5 mo 15.1 mo Hypertension 
(28.6%) 
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Jonasch 
et al. 
[45] 
Bevacizumab 
(see above); 
Capecitabine - 
chemotherape
utic agent, it is 
converted to 5-
fluorouracil, 
which inhibits 
the synthesis 
of thymidine 
monophosphat
e required for 
de novo 
synthesis of 
DNA; 
Gemcitabine - 
nucleoside 
anolog, blocks 
the DNA 
replication and 
inactivates the 
enzyme 
ribonucleotide 
reductase, 
which cannot 
produce the 
deoxyribonucle
otides for DNA 
replication and 
repair, cell 
apoptosis is 
induced 
Retrospecti
ve study 
Bevacizu
mab, 
capecitabi
ne and 
gemcitabi
ne 
5.9 mo 10.4 mo  
Chung 
et al. 
[47] 
Bevacizumab 
(see above); 
Capecitabine 
(see above); 
Gemcitabine 
(see above) 
Open-label, 
single arm, 
phase 2 
trial 
Bevacizu
mab, 
capecitabi
ne and 
gemcitabi
ne 
5.3 mo (3.9-
9.9) 
9.8 mo 
(6.2-14.9) 
Fatigue (21%), 
hand foot 
syndrome (7%), 
dyspnea (7%), 
emesis (7%), 
nausea (7%) 
Buti et 
al. [48] Bevacizumab 
(see above); 
IL-2 (see 
above); 
Interferon 
α (see 
above); Gemci
tabine (see 
above); 5-
fluorouracil - 
pyrimidine 
analog, 
thymidylate 
Multicenter, 
dose-
finding, 
phase 1 
trial 
Bevacizu
mab, IL-2, 
interferon 
α-2a, 
gemcitabi
ne and 5-
fluorourac
il 
TTP 6.4 mo 
(3.3-9.5) 
22.6 mo 
(9.6-35.6) 
Neutropenia 
(63%), 
thrombocytopen
ia (34%), fever 
(26%), pain and 
arthromyalgia 
(22%), asthenia 
(15%), 
leukopenia 
(11%), 
proteinuria 
(8%), 
hypertension 
(7%), 
hypertransamin
asemia (7%) 
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synthase 
inhibitor, thus 
blocks the 
synthesis of the 
thymidine, a 
nucleoside 
required for 
DNA replication 
Hainsw
orth et 
al. [49] 
Bevacizumab 
(see above); 
Erlotinib (see 
above); 
Imatinib - 
tyrosine kinase 
inhibitor, it 
blocks the 
activity of 
several 
enzymes, such 
as ABL, KIT, 
PDGF-R 
Multicenter, 
nonrandom
ized, phase 
2 trial 
Bevacizu
mab, 
erlotinib 
and 
imatinib 
8.9 mo (6.6-
10.9) 
17.2 mo 
(12.9-
21.0) 
Diarrhea (50%), 
rash (27%), 
fatigue (24%), 
nausea/vomiting 
(19%), 
proteinuria 
(12%), 
hypertension 
(7%), 
arthrealgia (5%) 
       
 
Table 1. Reviewed clinical studies on bevacizumab in renal cell carcinoma  
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 Mechanismo
f action 
Study 
design 
Experimente
d 
combination 
PFS OS Grade 3-4 
toxicities 
(incidence
) 
Topalian 
et al. [75] 
Nivolumab - 
inhibits PD-1, 
whose 
immune-
inhibitory 
effect 
mediates 
tumor 
immune 
escape, the 
PD-1/PD-L1 
interaction 
blocks Tcells 
functions and 
induces 
resistance of 
tumor cells to 
cytotoxic 
lymphocytes 
Phase 1, 
open-label, 
multicenter, 
multidose, 
dose-
escalation 
study 
Nivolumab 56 % (39-
73) at 24 
wk 
 Fatigue 
(5%); 
Dyspnea 
(8%) 
Brahmer 
et al. [76] 
Nivolumab 
(see above) 
Multi-
institutional, 
open-label, 
phase 1, 
dose-
escalation 
study 
Nivolumab   No 
Lipson et 
al. [77] 
Nivolumab 
(see above) 
Phase 1 
study 
Nivolumab    
Brahmer 
et al. [105] 
MDX-1105 – 
anti-PD-L1 
monoclonal 
antibody 
prevents the 
binding of 
PD-L1 to its 
receptor PD-
1, which 
enhances the 
T cells-
mediated 
immune 
response to 
tumor cells  
Phase 1, 
open-label, 
dose-
escalation, 
multidose 
study 
MDX-1105 53% (29-
77) at 24 
wk 
 Fatigue 
(8%); 
Dyspnea 
(5%) 
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Motzer et 
al. [79] 
Nivolumab 
(see above); 
Everolimus 
(see above) 
Randomized
, open-label, 
phase 3 
study 
Nivolumab 
versus 
Everolimus 
4.6 mo 
(3.7-5.4) 
with 
Nivolumab
; 4.4 mo 
(3.7-5.5) 
with 
Everolimu
s  
25 mo 
(21.8 to 
not 
estimable) 
with 
Nivolumab
; 19.6 mo 
(17.6-
23.1) with 
Everolimu
s 
Anemia 
(8%) with 
Everolimus 
McDermot
t et al. [78] 
Nivolumab 
(see above) 
Phase 1 
study 
Nivolumab  22.4 mo  
 
Table 2. Reviewed clinical studies on nivolumab in renal cell carcinoma  
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D
ow
nl
oa
de
d 
by
 [D
ipa
rtm
en
to 
di 
St
ud
i E
 R
eic
erc
he
], 
[D
an
iel
a T
err
ac
cia
no
] a
t 0
6:5
1 2
7 J
uly
 20
16
 
